Recon: Drugmakers sink after Marks’ ouster; Lilly’s drug slashes genetic heart disease risk in late-stage trial

• It’s RFK Jr.’s FDA now (STAT)
• Peter Marks, FDA’s top vaccine regulator, forced out (STAT)
• New FDA commissioner agreed to oust top vaccine regulator after private swearing-in (Politico)
• Ouster of FDA’s Peter Marks alarms a biopharma industry that saw him as an ally (STAT)
• Drugmakers sink after key FDA official ousted as Trump plans health overhaul (Reuters)
• HHS emergency response unit given two days to figure out its fate (STAT)
• Trump chooses Fox News contributor Sara Carter as next drug czar (STAT)
• Drugmakers sink after key FDA official ousted as Trump plans health overhaul (Reuters)
• Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial (Reuters)

• Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators (STAT)
• European institutions target ‘scientific asylum-seekers’ from US (The Hill)
• Chinese brain chip project speeds up human trials after first success (Reuters)
• Lassa fever kills 118 in Nigeria over last three months (Reuters)
• WHO proposing to cut jobs and slash budget by a fifth, memo shows (Reuters)

• Emotional whiplash for PTC Therapeutics (STAT)
• Novo Nordisk sets sights on new type of oral obesity drug (STAT)
• Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025 (Endpoints)
• Inspirna, which was preparing for a Phase 3 cancer trial, has folded (Endpoints)
• Lilly's heart disease drug could be dosed as little as once a year, study shows (Endpoints)
• Corcept's ovarian cancer drug cuts disease progression in study, shares jump (Reuters)
• Exclusive: Transcend notches Phase 2 win to treat PTSD, invigorating budding neuroplastogen class (Endpoints)
• BiomX’s phage therapy succeeds in Phase 2 diabetic bone infection study (Endpoints)
• Exclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and others (Endpoints)
• Vertex’s second-generation diabetes cell therapy fails early-stage study (Endpoints)

• FDA OKs first at-home test for 3 STIs (MedTech Dive)
• Tandem eyes Medicare coverage expansion for Type 2 (MedTech Dive)
• How Cutting Edge Technology Is Changing Risk Management In the EU (MedTech Insight)
• LSI 2025: Vektor Medical CEO Says ‘Arrhythmia Is The Biggest Health Care Crisis Nobody Talks About,’ vMap Treats It With 91.1% Accuracy (MedTech Insight)

• Requirements for Mandatory Foodborne Pathogen WGS Analysis, Data Submission in EU (Food Safety)
• Boar’s Head Appoints Natalie Dyenson as Chief Food Safety Officer (Food Safety)

• Utah bans fluoride in public drinking water, a first in the U.S. (STAT)
• Amgen loses its battle against Colorado over a prescription drug affordability board (STAT)
• Big Tobacco targets Trump in hope - and fear - of change (Reuters)
• It’s a Bird, It’s a Plane, It’s Operation Stork Speed (FDA Law Blog)